Validation of biomarkers of aging

Mahdi Moqri; Chiara Herzog; Jesse R Poganik; Kejun Ying; Jamie N Justice; Daniel W Belsky; Albert T Higgins-Chen; Brian H Chen; Alan A Cohen; Georg Fuellen; Sara Hägg; Riccardo E Marioni; Martin Widschwendter; Kristen Fortney; Peter O Fedichev; Alex Zhavoronkov; Nir Barzilai; Jessica Lasky-Su; Douglas P Kiel; Brian K Kennedy; Steven Cummings; P Eline Slagboom; Eric Verdin; Andrea B Maier; Vittorio Sebastiano; Michael P Snyder; Vadim N Gladyshev; Steve Horvath; Luigi Ferrucci

doi:10.1038/s41591-023-02784-9

Validation of biomarkers of aging

Mahdi Moqri, Chiara Herzog, Jesse R Poganik, Kejun Ying, Jamie N Justice, Daniel W Belsky, Albert T Higgins-Chen, Brian H Chen, Alan A Cohen, Georg Fuellen, Sara Hägg, Riccardo E Marioni, Martin Widschwendter, Kristen Fortney, Peter O Fedichev, Alex Zhavoronkov, Nir Barzilai, Jessica Lasky-Su, Douglas P Kiel, Brian K KennedySteven Cummings, P Eline Slagboom, Eric Verdin, Andrea B Maier, Vittorio Sebastiano, Michael P Snyder, Vadim N Gladyshev, Steve Horvath, Luigi Ferrucci

Research output: Contribution to Journal › Review article › Academic › peer-review

Abstract

The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.

Original language	English
Pages (from-to)	360-372
Number of pages	13
Journal	Nature Medicine
Volume	30
Issue number	2
DOIs	https://doi.org/10.1038/s41591-023-02784-9
Publication status	Published - Feb 2024

Bibliographical note

Funding

This work was supported in part by the Intramural Research Program of the National Institute on Aging, NIH, and grants from the National Institute on Aging and Hevolution Foundation. D.P.K. was supported by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041398). We are very grateful to D.M. Wilson III for many suggestions during the writing of this paper. We express our gratitude to all members of the Biomarkers of Aging Consortium Roadmap Group ( https://www.agingconsortium.org/ ) for their fruitful discussions that helped to define the scope and direction of this work. The list of authors reflects Roadmap Group members who directly contributed to or refined the manuscript.

Funders	Funder number
National Institute on Aging and Hevolution Foundation
National Institutes of Health
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases	R01AR041398

Access to Document

10.1038/s41591-023-02784-9

Persistent URL (handle)

Copy link address

Cite this

Moqri, M., Herzog, C., Poganik, J. R., Ying, K., Justice, J. N., Belsky, D. W., Higgins-Chen, A. T., Chen, B. H., Cohen, A. A., Fuellen, G., Hägg, S., Marioni, R. E., Widschwendter, M., Fortney, K., Fedichev, P. O., Zhavoronkov, A., Barzilai, N., Lasky-Su, J., Kiel, D. P., ... Ferrucci, L. (2024). Validation of biomarkers of aging. Nature Medicine, 30(2), 360-372. https://doi.org/10.1038/s41591-023-02784-9

@article{af1c9ce48c374ae99dbfc2536f07a9f0,

title = "Validation of biomarkers of aging",

abstract = "The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.",

author = "Mahdi Moqri and Chiara Herzog and Poganik, {Jesse R} and Kejun Ying and Justice, {Jamie N} and Belsky, {Daniel W} and Higgins-Chen, {Albert T} and Chen, {Brian H} and Cohen, {Alan A} and Georg Fuellen and Sara H{\"a}gg and Marioni, {Riccardo E} and Martin Widschwendter and Kristen Fortney and Fedichev, {Peter O} and Alex Zhavoronkov and Nir Barzilai and Jessica Lasky-Su and Kiel, {Douglas P} and Kennedy, {Brian K} and Steven Cummings and Slagboom, {P Eline} and Eric Verdin and Maier, {Andrea B} and Vittorio Sebastiano and Snyder, {Michael P} and Gladyshev, {Vadim N} and Steve Horvath and Luigi Ferrucci",

note = "{\textcopyright} 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",

year = "2024",

month = feb,

doi = "10.1038/s41591-023-02784-9",

language = "English",

volume = "30",

pages = "360--372",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "2",

}

Moqri, M, Herzog, C, Poganik, JR, Ying, K, Justice, JN, Belsky, DW, Higgins-Chen, AT, Chen, BH, Cohen, AA, Fuellen, G, Hägg, S, Marioni, RE, Widschwendter, M, Fortney, K, Fedichev, PO, Zhavoronkov, A, Barzilai, N, Lasky-Su, J, Kiel, DP, Kennedy, BK, Cummings, S, Slagboom, PE, Verdin, E, Maier, AB, Sebastiano, V, Snyder, MP, Gladyshev, VN, Horvath, S & Ferrucci, L 2024, 'Validation of biomarkers of aging', Nature Medicine, vol. 30, no. 2, pp. 360-372. https://doi.org/10.1038/s41591-023-02784-9

TY - JOUR

T1 - Validation of biomarkers of aging

AU - Moqri, Mahdi

AU - Herzog, Chiara

AU - Poganik, Jesse R

AU - Ying, Kejun

AU - Justice, Jamie N

AU - Belsky, Daniel W

AU - Higgins-Chen, Albert T

AU - Chen, Brian H

AU - Cohen, Alan A

AU - Fuellen, Georg

AU - Hägg, Sara

AU - Marioni, Riccardo E

AU - Widschwendter, Martin

AU - Fortney, Kristen

AU - Fedichev, Peter O

AU - Zhavoronkov, Alex

AU - Barzilai, Nir

AU - Lasky-Su, Jessica

AU - Kiel, Douglas P

AU - Kennedy, Brian K

AU - Cummings, Steven

AU - Slagboom, P Eline

AU - Verdin, Eric

AU - Maier, Andrea B

AU - Sebastiano, Vittorio

AU - Snyder, Michael P

AU - Gladyshev, Vadim N

AU - Horvath, Steve

AU - Ferrucci, Luigi

PY - 2024/2

Y1 - 2024/2

N2 - The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.

AB - The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.

U2 - 10.1038/s41591-023-02784-9

DO - 10.1038/s41591-023-02784-9

M3 - Review article

C2 - 38355974

SN - 1078-8956

VL - 30

SP - 360

EP - 372

JO - Nature Medicine

JF - Nature Medicine

IS - 2

ER -

Validation of biomarkers of aging

Abstract

Bibliographical note

Funding

Access to Document

Persistent URL (handle)

Fingerprint

Cite this